Skip to main content
logo
Curanex Pharmaceuticals Inc (CURX)
NASDAQ: CURX · Real-Time Price · USD
0.2052
+0.0142 (7.43%)
At close: Jul 31, 2026

Curanex Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-7.24-4.23-0.36-0.02-0.02
Depreciation & Amortization
0.110.08-00.02
Other Adjustments
--0.07--
Changes in Inventories
---00.02
Changes in Accounts Payable
-0.12-00.01--
Changes in Accrued Expenses
0.010-00.01-
Changes in Other Operating Activities
-4.05-6.34-0.27--0.02
Operating Cash Flow
-11.29-10.48-0.56-00
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Issuance of Common Stock
-15.660.63--
Net Common Stock Issued (Repurchased)
-15.660.63--
Issuance of Preferred Stock
--0--
Net Preferred Stock Issued (Repurchased)
--0--
Other Financing Activities
0.2-0.35-0.07-0
Financing Cash Flow
15.1115.310.630.07-0

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
3.824.820.070.070

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-11.29-10.48-0.56-00
Free Cash Flow Growth
-----
FCF Margin
----12.83%
Free Cash Flow Per Share
-0.42-0.41-0.04-0.000.01
Levered Free Cash Flow
-11.28-10.48-0.63-00
Unlevered Free Cash Flow
-11.33-10.5-0.63-00
SEC Filings: 10-K · 10-Q